Provectus Receives Patent Allowance From U.S. Patent Office

Business Wire, Oct 30, 2007

Patent to Protect Radiotherapy Drugs

KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) has received allowance of its U.S. patent application, protecting therapeutic agents based on a novel radiodense analog of its lead therapeutic product PV-10, from the United States Patent and Trademark Office (USPTO).

The pending patent covers therapeutic agents that are used in conjunction with radiation therapy to improve the efficiency and specificity of radiation for oncology. The agents, called radiosensitizers, are based on a novel molecule related to PV-10, the Company's lead oncology product.

"Like PV-10, these new agents are not radioactive; instead they serve to magnify the cancer-killing effects of radiation therapy by selectively sensitizing cancerous tissue to applied radiation," noted Craig Dees, PhD, CEO of Provectus. "The hope is that this can serve to dramatically reduce the amount of radiation needed and minimize its effects in normal tissue."

Dees continued: "We remain focused on the therapeutic uses of PV-10 as a stand-alone product category, but cannot ignore the large potential value of these products for cancer markets worldwide. Similar to our recently announced PET technology, protection of our platform technology in all potential areas of medical use enhances value for our shareholders."

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting clinical trials of their proprietary drugs PV-10 as a therapy for melanoma and breast cancer, and PH-10 as a topical treatment for severe psoriasis and eczema. The Company recently commenced Phase 2 clinical testing of PV-10 for melanoma and has received orphan drug designation from the FDA for melanoma. Initial Phase 1 clinical trial objectives for PV-10 for breast cancer were completed in April 2006, but the trial has been extended to more properly determine optimal dosing. Additionally, the Company is about to begin Phase 2 of clinical testing of its topical product PH-10 for psoriasis. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact The Investor Relations Group via the information provided below.

Forward-Looking Statements

The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.